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The introduction of daylight-mediated photodynamic 
therapy (d-PDT) has resulted in pain-free field treatment 
of multiple actinic keratoses (AK) of the face and scalp 
(1). Erythema and crusting may be less pronounced after 
d-PDT compared with conventional PDT (c-PDT) using 
red light (2, 3). During PDT of multiple AK of the face 
and scalp, patients are affected by inflammation, which 
may cause absence from work or social activities. In a 
recent study we introduced the concept of pulse-PDT, in 
which methyl aminolevulinate (MAL) cream is applied 
for only 30 min under occlusion and then removed to 
ensure selective accumulation of the photosensitizer pro-
toporphyrin IX (PpIX) in the mitochondria and cytosol of 
the diseased cells (4). The study showed that the use of 
pulse-PDT could reduce erythema after PDT of multiple 
AK on the face and scalp (4). The use of a super-potent 
corticosteroid before and just after pulse-PDT further 
reduced erythema. 
The objective of this randomized study was to eva-
luate whether the combination of pulse-corticosteroid-
daylight-PDT (PS-d-PDT) would result in less post-PDT 
erythema than d-PDT without affecting the efficacy of 
the treatment of multiple AK on the face and scalp. A 
further aim was to clarify whether the use of brimonidine 
tartrate (BT), a selective α2-adrenergic receptor agonist, 
could result in a further short-term reduction in PDT-
induced erythema.
MATERIALS AND METHODS 
Twenty-five male patients with a total of 823 AK were included in 
the study. AK on the face or scalp were marked in 2 symmetrical 
squared areas and randomized to d-PDT or PS-d-PDT, respectively. 
After lesion counting and mapping, a sunscreen (Actinica® SPF 
50+, Galderma, Uppsala, Sweden) was applied. Following lesion 
preparation with a curette, MAL cream (Metvix®, Galderma) was 
applied to both treatment areas without occlusion. After 30 min, the 
MAL cream was removed in the area randomized to PS-d-PDT and 
super-potent glucocorticosteroid (Dermovat®, GlaxoSmithKline, 
Broendby Denmark) was applied. The MAL was not removed 
from the d-PDT until after daylight exposure. Patients exposed 
themselves continuously to daylight for 2 h, after which they stayed 
indoors for the remainder of the day. Erythema was evaluated 24 
h after PDT, at which time BT gel was applied in both treatment 
areas, and erythema was re-evaluated 30 min later. Erythema was 
measured using a skin reflectance meter (Optimize Scientific 558; 
Chromo-Light, Vedbaek, Denmark) (5) and evaluated visually 
by the investigator using a 4-point scale. Patients scored the pain 
using a numerical scale (0–10) in both areas every 30 min during 
daylight exposure. 
The study was approved by the ethics committee of Region 
Hovedstaden (H-4-2011-151). Statistical analyses were performed 
with GraphPad Prism® (GraphPad Software Inc., USA). Wilcoxon 
matched-pairs signed rank test was used to compare paired data 
and for correlations Spearman R correlation was used. A p-value 
< 0.05 was considered significant.
RESULTS
No difference was found between the 2 treatment areas 
in baseline characteristics, such as lesion count and ery-
thema. Ninety percent of the lesions were grade I AK. 
One patient was excluded from the BT part of the study 
due to treatment with MAO-inhibitors. 
The visually evaluated erythema one day after treat-
ment was less in areas treated with PS-d-PDT compared 
with d-PDT (p = 0.0032). 
Measured erythema was significantly increased 
the day after both treatments compared with baseline 
(p < 0.0001). Median erythema was significantly higher 
in the d-PDT areas than in the PS-d-PDT areas the day 
after treatment (p = 0.028) (Table I). 
The use of BT on the treated areas 1 day after treatment 
significantly reduced erythema (p < 0.0001) (Table I). 
BT removed PDT-induced erythema as no significant 
difference was found between erythema before PDT 
and after BT in either d-PDT or PS-d-PDT treated areas 
(p = 0.77 and p = 0.27, respectively). Both treatments 
were almost pain-free, with a median maximal pain score 
of 1 (p = 0.81). No significant difference in efficacy was 
found between the 2 treatment areas (p = 0.42) (Table I). 
At 3-month follow-up a mean of 1.4 new AK had 
developed in the d-PDT-treated areas, compared with 
2.6 new AK in the PS-d-PDT-treated areas (p = 0.012). 
Lesion response rate was not associated with increased 
erythema (p = 0.51 and p = 0.78). 
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Table I. Erythema and number of actinic keratosis before and after 
treatment in both areas
d-PDT
Median (IQR)
PS-d-PDT
Median (IQR)
p- 
value
Erythema
Baseline 39.9 (35.2–43.9) 38.6 (33.1–41.9) 0.32
24 h after PDT 47.8 (41.1–51.0) 44.6 (41.0–48.3) 0.0028
24 h after PDT and BT 42.4 (36.2–45.6) 37.8 (33.6–42.0) 0.015
Actinic keratosis
Baseline 15 (13–20) 14 (12–21) 0.59
3-month lesion response rate (%) 75.8 (64.7–86.7) 80.0 (66.7–87.5) 0.42
PDT: photodynamic therapy; BT: brimonidine tartrate; d-PDT: daylight-PDT; PS-
d-PDT: pulse-steroid-daylight-PDT; IQR: interquartile range.
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DISCUSSION
The use of PS-d-PDT resulted in only a minor reduction 
in erythema compared with d-PDT. In an earlier study 
PS-d-PDT more than halved the increase in erythema 
seen after c-PDT (4). As reported in other studies (2, 3), 
d-PDT induced much lower post-treatment erythema 
(21.2%), than c-PDT with red light (38.7%) (4), which 
makes it more difficult to achieve a significant reduction 
in erythema using the pulse-steroid approach. The use 
of pulse-steroid did not affect the efficacy of d-PDT or 
of c-PDT (4). 
Super-potent corticosteroid was applied only once 
before exposure to daylight and not twice (before and 
after PDT) as in the former c-PDT studies (4, 6). Single 
application was used to ensure that corticosteroid was 
applied only to the PS-d-PDT area, but may explain 
some of the reduced effect on erythema in the present 
study. Further studies are needed to determine whether 
application of corticosteroid once daily after PDT would 
reduce erythema further. 
The number of new AK in the treated areas 3 months 
after treatment was significantly higher in the PS-d-PDT-
treated areas compared with d-PDT-treated areas. This 
difference was not found using conventional PDT (4, 6). 
The reason for more new AK lesion after PS-d-PDT is 
unknown, but may be caused by a less effective treat ment 
of subclinical lesions, which could be evaluated using 
confocal microscopy. However, since no reduced efficacy 
of PS-d-PDT is found for visible AK this theory is not li-
kely. The enhanced number of new lesions raises concern 
regarding the long-term efficacy of PS-d-PDT for AK. 
We found that application of BT significantly redu-
ced PDT-induced erythema 24 h after d-PDT. BT is a 
highly selective α2-adrenergic receptor agonist with 
potent vasoconstrictive activity, which is now approved 
for the treatment of facial erythema associated with 
rosacea (7). In 9 patients, BT gel reduced the erythema 
to a level below the redness before PDT. BT was only 
applied once 24 h after treatment, without affecting the 
efficacy of the treatment, since efficacy was comparable 
with other d-PDT studies (1, 8). It may therefore be safe 
for the patient to use a single application of BT before 
attending work-related and social activities. However, 
further research is needed to determine whether daily 
application of BT might affect the efficacy of PDT for 
AK due to vasoconstriction leading to less inflammation.
In conclusion, d-PDT induced less erythema than seen 
after conventional PDT. The use of PS-d-PDT resulted 
in a minor reduction in erythema compared with d-PDT. 
Application of BT significantly reduced post-treatment 
erythema and may be an easy way to make PDT in visible 
areas more acceptable and reduce downtime. 
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